title: Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels.
abstract: The aim of our study was to evaluate the lipoprotein changes that occur during acute coronary events, and to determine the lipoprotein threshold levels that identify patients who require future statin therapy. Lipoprotein levels were measured at admission, at 6 hours, the morning after admission, before discharge, and 3 months after discharge in patients with myocardial infarction and unstable angina. Patients with myocardial infarction on thrombolytic therapy (n = 63) and patients with unstable angina (n = 33) had a decrease in low-density lipoprotein (LDL) cholesterol levels < or = 24 hours after admission (-12 +/- 20% and -6 +/- 23%, respectively), but these levels returned to baseline before discharge. In patients with myocardial infarction who did not receive thrombolytic therapy (n = 37), the decrease was more gradual and peaked before hospital discharge (-7 +/- 19%). There was good correlation between LDL cholesterol levels at admission and after discharge, especially in normotriglyceridemic patients. Over 90% of patients with LDL cholesterol > or = 125 mg/dl on the morning after admission were candidates for statin therapy after discharge. Thus, the need for future statin therapy can be predicted with fair reliability during the initial 24 hours after admission. However, elevated baseline triglyceride levels significantly affect these LDL cholesterol changes and complicate prediction of long-term lipoprotein levels.
authors.affiliation: Department of Cardiology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. yaakovh@bgumail.ac.il
authors.forename: Yaakov
authors.initials: Y
authors.lastname: Henkin
authors.forename: Eugene
authors.initials: E
authors.lastname: Crystal
authors.forename: Yury
authors.initials: Y
authors.lastname: Goldberg
authors.forename: Michael
authors.initials: M
authors.lastname: Friger
authors.forename: Jonathan
authors.initials: J
authors.lastname: Lorber
authors.forename: Irene
authors.initials: I
authors.lastname: Zuili
authors.forename: Shraga
authors.initials: S
authors.lastname: Shany
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001055:Apolipoproteins B / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006760:Hospitalization; D006801:Humans; D006949:Hyperlipidemias / Q000175:diagnosis* / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D011237:Predictive Value of Tests; D015912:Thrombolytic Therapy; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol